Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis.
Reid M, Agbassi YJP, Arinaminpathy N, Bercasio A, Bhargava A, Bhargava M, Bloom A, Cattamanchi A, Chaisson R, Chin D, Churchyard G, Cox H, Denkinger CM, Ditiu L, Dowdy D, Dybul M, Fauci A, Fedaku E, Gidado M, Harrington M, Hauser J, Heitkamp P, Herbert N, Herna Sari A, Hopewell P, Kendall E, Khan A, Kim A, Koek I, Kondratyuk S, Krishnan N, Ku CC, Lessem E, McConnell EV, Nahid P, Oliver M, Pai M, Raviglione M, Ryckman T, Schäferhoff M, Silva S, Small P, Stallworthy G, Temesgen Z, van Weezenbeek K, Vassall A, Velásquez GE, Venkatesan N, Yamey G, Zimmerman A, Jamison D, Swaminathan S, Goosby E. Reid M, et al. Among authors: lessem e. Lancet. 2023 Oct 21;402(10411):1473-1498. doi: 10.1016/S0140-6736(23)01379-X. Epub 2023 Sep 13. Lancet. 2023. PMID: 37716363 Review. No abstract available.
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis.
Dheda K, Gumbo T, Maartens G, Dooley KE, Murray M, Furin J, Nardell EA, Warren RM; Lancet Respiratory Medicine drug-resistant tuberculosis Commission group. Dheda K, et al. Lancet Respir Med. 2019 Sep;7(9):820-826. doi: 10.1016/S2213-2600(19)30263-2. Lancet Respir Med. 2019. PMID: 31486393 Review.
Compassionate and optimum use of new tuberculosis drugs.
Reed C, Mason L, Cox H, Seaworth B, Lessem E, Furin J. Reed C, et al. Among authors: lessem e. Lancet Infect Dis. 2015 Oct;15(10):1131. doi: 10.1016/S1473-3099(15)00294-7. Epub 2015 Sep 20. Lancet Infect Dis. 2015. PMID: 26461942 No abstract available.
The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.
Dheda K, Gumbo T, Maartens G, Dooley KE, McNerney R, Murray M, Furin J, Nardell EA, London L, Lessem E, Theron G, van Helden P, Niemann S, Merker M, Dowdy D, Van Rie A, Siu GK, Pasipanodya JG, Rodrigues C, Clark TG, Sirgel FA, Esmail A, Lin HH, Atre SR, Schaaf HS, Chang KC, Lange C, Nahid P, Udwadia ZF, Horsburgh CR Jr, Churchyard GJ, Menzies D, Hesseling AC, Nuermberger E, McIlleron H, Fennelly KP, Goemaere E, Jaramillo E, Low M, Jara CM, Padayatchi N, Warren RM. Dheda K, et al. Among authors: lessem e. Lancet Respir Med. 2017 Mar 15:S2213-2600(17)30079-6. doi: 10.1016/S2213-2600(17)30079-6. Online ahead of print. Lancet Respir Med. 2017. PMID: 28344011 Review.
Adoption and uptake of the lateral flow urine LAM test in countries with high tuberculosis and HIV/AIDS burden: current landscape and barriers.
Singhroy DN, MacLean E, Kohli M, Lessem E, Branigan D, England K, Suleiman K, Drain PK, Ruhwald M, Schumacher S, Denkinger CM, Waning B, Van Gemert W, Pai M. Singhroy DN, et al. Among authors: lessem e. Gates Open Res. 2020 Apr 7;4:24. doi: 10.12688/gatesopenres.13112.2. eCollection 2020. Gates Open Res. 2020. PMID: 32185366 Free PMC article.
The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?
Reuter A, Tisile P, von Delft D, Cox H, Cox V, Ditiu L, Garcia-Prats A, Koenig S, Lessem E, Nathavitharana R, Seddon JA, Stillo J, von Delft A, Furin J. Reuter A, et al. Among authors: lessem e. Int J Tuberc Lung Dis. 2017 Nov 1;21(11):1114-1126. doi: 10.5588/ijtld.17.0468. Int J Tuberc Lung Dis. 2017. PMID: 29037291 Review.
Informed use of bedaquiline for tuberculosis.
Lessem EM, Bernardo J, Reed C, Wegener DH. Lessem EM, et al. Lancet. 2015 May 2;385(9979):1724. doi: 10.1016/S0140-6736(15)60885-6. Lancet. 2015. PMID: 25943933 No abstract available.
High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.
Dorman SE, Nahid P, Kurbatova EV, Goldberg SV, Bozeman L, Burman WJ, Chang KC, Chen M, Cotton M, Dooley KE, Engle M, Feng PJ, Fletcher CV, Ha P, Heilig CM, Johnson JL, Lessem E, Metchock B, Miro JM, Nhung NV, Pettit AC, Phillips PPJ, Podany AT, Purfield AE, Robergeau K, Samaneka W, Scott NA, Sizemore E, Vernon A, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group and the Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: lessem e. Contemp Clin Trials. 2020 Mar;90:105938. doi: 10.1016/j.cct.2020.105938. Epub 2020 Jan 22. Contemp Clin Trials. 2020. PMID: 31981713 Free PMC article.
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement.
Nachman S, Ahmed A, Amanullah F, Becerra MC, Botgros R, Brigden G, Browning R, Gardiner E, Hafner R, Hesseling A, How C, Jean-Philippe P, Lessem E, Makhene M, Mbelle N, Marais B, McIlleron H, McNeeley DF, Mendel C, Murray S, Navarro E, Anyalechi EG, Porcalla AR, Powell C, Powell M, Rigaud M, Rouzier V, Samson P, Schaaf HS, Shah S, Starke J, Swaminathan S, Wobudeya E, Worrell C. Nachman S, et al. Among authors: lessem e. Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9. Epub 2015 May 6. Lancet Infect Dis. 2015. PMID: 25957923 Free PMC article. Review.
26 results